Recent Pfizer Press Releases

  • 6/6/16 9:00 am EDT
    • First pivotal study for Merck KGaA, Darmstadt, Germany, and Pfizer’s investigational anti-PD-L1 antibody avelumab shows clinically meaningful tumor responses in pre-treated metastatic Merkel cell carcinoma (MCC)
    • International, multicenter Phase II study results in metastatic MCC with 88 patients represents largest data set of any anti-PD-L1/PD-1 reported in this patient population
    • Plan to submit to regulatory authorities based on these results
    CHICAGO--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab*, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%†), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second ormore...
  • 6/6/16 8:00 am EDT

    Study Results Presented as Oral Abstract at ASCO 2016

    CHICAGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. These data were presented today in an oral presentation atmore...
  • 6/4/16 8:00 am EDT

    Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1 inhibitor, in patients with advanced solid tumors. This is the first reported study of a 4-1BB agonist combined with a checkpoint inhibitor. Encouraging safety data from the study weremore...
  • 5/23/16 7:00 am EDT

    Black triangle indicating additional safety monitoring requirement for CHAMPIX in the EU has been removed

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX® (varenicline) have been updated to include safety and efficacy data from the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial.1 As part of the update, the black triangle symbol, which indicated that additional safety monitoring for CHAMPIX in the EU was required, has been removed.more...
  • 5/20/16 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older. The acceptance marks the beginning of the regulatory review process for thismore...
  • 5/18/16 5:30 pm EDT
    • 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer
    • Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma
    • Data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers
    • JAVELIN clinical program rapidly accelerating

    ASCO Abstract #
    8503, 9508, 4009, 4514, 4516, 9036, TPS4134, TPS4135, TPS9105, 3055, TPS3106, 5533, TPS5600, TPS4580

    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development program, include new study results from a number of difficult-to-treatmore...
  • 5/18/16 5:00 pm EDT

    More than 40 accepted abstracts highlight innovation in immuno-oncology and other novel modalities across multiple tumor types

    Pfizer invites public to view and listen to webcast of conference call with analysts on Wednesday, June 8 at 10 a.m. EDT to review oncology business and ASCO data presentations

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer’s internal andmore...
  • 5/17/16 8:00 am EDT

    Findings Show the Importance of Patient and Physician Dialogue to Achieve Optimal Disease Management Outcomes

    NEW YORK--(BUSINESS WIRE)--Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management. The findings from more than 1,700 rheumatologists* in 15 countries builds upon results from the global patient survey findings, released in 2015, involving 3,900 adults living with RA. The combined survey data demonstrate disconnects between patients and physiciansmore...
  • 5/13/16 6:30 am EDT

    Secondary Data Support That TRUMENBA® Protects Against Additional Meningococcal Serogroup B Strains

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responsesmore...
  • 5/11/16 8:00 am EDT
    • Metastatic Research Accounts for Only About 7 Percent of Total Breast Cancer Research Investment1
    • Awards Complement Ongoing Initiative, Which has Reached More Than 40 Million People to Date
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public’s knowledge of MBC and bringing greater attention to the uniquemore...